Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).Audreylie Lemelin, Daniel Yick Chin Heng, Connor Wells et al.|Journal of Clinical Oncology|2023Cited by 0